Photo of a clean colon

About MoviPrep

See why MoviPrep is the #1-prescribed branded purgative in the United States1

  • Proven 89% excellent or good cleansing when used as a split dose; efficacy that has been proven in clinical trials2
  • Low-volume polyethylene glycol (PEG) bowel prep with ascorbic acid, sodium ascorbate, and sodium sulfate to increase stool volume2
  • Proven more tolerable than 4-L bowel preparations, with less nausea, vomiting, and abdominal pain3
    • In clinical trials, no differences seen in safety and tolerability between younger and geriatric patients2
    • Does not contain bisacodyl
  • Provides osmotic and electrolyte balance to help keep patients hydrated2

MoviPrep is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.2

Efficacy

MoviPrep had excellent or good overall colon cleansing when administered with a PM|AM Split Dosing™ regimen.2

Effectiveness of Overall Colon Cleansing in the Study of MoviPrep vs 4-Liter Polyethylene Glycol Plus Electrolytes Solution

Responders
A† or B‡ (%)		 C§ (%) D|| (%)
MoviPrep
(N=153)		 88.9 9.8 1.3
4L PEG + E*
(N=155)		 94.8 4.5 0.6

*4L PEG + E is 4-liter polyethylene glycol plus electrolytes solution.
†A: Colon empty and clean or presence of clear liquid, but easily removed by suction.
‡B: Brown liquid or semisolid remaining amounts of stool, fully removable by suction or displaceable, thus allowing a complete visualization of the gut mucosa.
§C: Semisolid amounts of stool, only partially removable with a risk of incomplete visualization of the gut mucosa.
||D: Semisolid or solid amounts of stool; consequently colonoscopy incomplete or needed to be terminated.
4-L PEG+E's responder rate was not significantly higher than MoviPrep's responder rate.

Mechanism of action and ingredients

MoviPrep produces a watery stool leading to cleansing of the colon. The osmotic activity of PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken with 1 L of additional clear fluid, usually results in no net absorption or excretion of ions or water. MoviPrep is an osmotic laxative with electrolytes.2

The active ingredients of MoviPrep are PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid.2

Back to top

Tolerability and safety

Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness.2

In Clinical Trials Using Split Dosing, the Most Common Drug-Related Adverse Reactions* (≥2%) in the Study of MoviPrep vs 4-Liter Polyethylene Glycol Plus Electrolytes Solution

Adverse event Patients, %
MoviPrep
(n=180)		 4-L PEG + E†
(n=179)
Malaise 19.4 17.9
Nausea 14.4 20.1
Abdominal pain 13.3 15.1
Vomiting 7.8 12.8
Upper abdominal pain 5.6 6.1
Dyspepsia 2.8 1.1

*Drug-related adverse reactions were adverse events that were possibly, probably, or definitely related to the study drug.
†4L PEG + E is 4-liter polyethylene glycol plus electrolytes solution.

Dosage and administration

The MoviPrep dose for bowel preparation for adult patients is 2 L (approximately 64 oz) of MoviPrep solution (with 1 additional liter of clear fluids), taken orally prior to the colonoscopy in either a split dose or an evening-only dose. Learn about both preparation methods.2

Preparation of the MoviPrep solution

MoviPrep solution is prepared by emptying the contents of 1 pouch A and 1 pouch B into a suitable glass container (or the container provided) and adding to the container 1 L of lukewarm water.2 Mix the solution to ensure that the ingredients are completely dissolved. If the patient prefers, the MoviPrep solution can be refrigerated prior to drinking. The reconstituted solution should be used within 24 hours. After consumption of the first liter of MoviPrep solution, the above mixing procedure should be repeated with the second pouch A and pouch B to reconstitute the second liter of the MoviPrep solution.

Patients can drink any clear liquid of their choice, such as2

  • Water
  • Clear soup
  • Fruit juice without pulp
  • Soft drinks
  • Tea and/or coffee without milk

Important Safety Information about MOVIPREP

MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MOVIPREP should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. MOVIPREP contains 233 mg of phenylalanine per treatment. Advise patients to hydrate adequately before, during, and after the use of MOVIPREP.

You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.

Complete Prescribing Information pdf icon

For Dummies is a registered trademark of Wiley Publishing, Inc.

References: 1. Medi-Span® Price Rx® [database online]. Indianapolis, IN: Wolters Kluwer Health. http://www.medispan.com/drug-pricing-analysis-pricerx.aspx. Accessed July 18, 2011.
2. MoviPrep [prescribing information]. Morrisville, NC. Salix Pharmaceuticals, Inc; 2011. 3. Cohen LB, Tennyson C. Bowel preparation for colonoscopy: maximizing efficacy, minimizing risk. Gastroenterol Endosc News. 2007;5(special ed):23-31.